Adenovirus-Derived Vectors for Prostate Cancer Gene Therapy

Author(s):
Vrij, J. de; Willemsen, R.A.; Lindholm, L.; Hoeben, R.C. (0000-0001-9443-8377); Bangma, C.H.; Barber, C.; Behr, J.P.; Briggs, S.; Carlisle, R.; Cheng, W.S.; Dautzenberg, I.J.; Ridder, C. de; Dzojic, H.; Erbacher, P.; Essand, M.; Fisher, K.; Frazier, A.; Georgopoulos, L.J.; Jennings, I.; Kochanek, S.; Koppers-Lalic, D.; Kraaij, R.; Kreppel, F.; Magnusson, M.; Maitland, N.; Neuberg, P.; Nugent, R.; Ogris, M.; Remy, J.S.; Scaife, M.; Schenk-Braat, E.; Schooten, E.; Seymour, L.; Slade, M.; Szyjanowicz, P.; Totterman, T.; Uil, T.G.; Ulbrich, K.; Weel, L. van der; Weerden, W. van; Wagner, E.; Zuber, G.; GIANT Consortium
Published
2010
Publication type
Article / Letter to editor

Abstract

Prostate cancer is a leading cause of death among men in Western countries. Whereas the survival rate approaches 100% for patients with localized cancer, the results of treatment in patients with metastasized prostate cancer at diagnosis are much less successful. The patients are usually presented with a variety of treatment options, but therapeutic interventions in prostate cancer are associated with frequent adverse side effects. Gene therapy and oncolytic virus therapy may constitute new strategies. Already a wide variety of preclinical studies has demonstrated the therapeutic potential of such approaches, with oncolytic prostate-specific adenoviruses as the most prominent vector. The state of the art and future prospects of gene therapy in prostate cancer are reviewed, with a focus on adenoviral vectors. We summarize advances in adenovirus technology for prostate cancer treatment and highlight areas where further developments are necessary.

conditionally replicating adenovirus polymer-coated adenovirus membrane antigen psma capsid protein-ix t-cell-receptor polyethylene-glycol tumor-cells in-vivo urokinase receptor oncolytic virus
Date issued
2010-07-31
Language
English
Is part of
Human Gene Therapy (2010), Vol. 21, no. 7, p. 795-805
hdl
1887/109362